← Back to screener

Cytek Biosciences, Inc. CTKB

Rank #1764 · Nasdaq · $0.8B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
42.7
P/E
-65.2
P/B
2.00
ROE
-3.1%
Op. Margin
-14.4%
Debt Ratio
26%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -65.2x, P/B 2.00x. Ranks in the top 53% of the universe.

Profitability ★☆☆☆☆
Weak

ROE -3.1%. Ranks in the top 76% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 26%. Ranks in the top 15% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★☆
Good

Revenue growth of 17.7% year over year. Ranks in the top 22% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021$0.1B$0.0B$0.0B$-0.0B14.7-100
2022$0.0B$0.0B$0.0B$0.0B1923.8139
2023$0.0B$0.0B$0.0B$-0.0B419.9-586
2024$0.2B$-0.0B$0.0B$0.4B-1.125
2025$0.2B$-0.0B$-0.0B$0.4B-14.426

← See the full screener